{"id":"q8003","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By selectively inhibiting the kappa opioid receptor, Q8003 aims to reduce the dysphoric effects associated with kappa opioid receptor activation, which are thought to contribute to the development of opioid use disorder. This mechanism is distinct from traditional opioid receptor agonists, which activate the mu opioid receptor and can lead to euphoria and dependence.","oneSentence":"Q8003 is a selective inhibitor of the kappa opioid receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:46.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT04696445","phase":"","title":"Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-10-01","conditions":"Opioid Use, Side Effect of Drug, Postoperative Pain","enrollment":34},{"nctId":"NCT03435692","phase":"NA","title":"Post Operative Pain Control After Pediatric Hip Surgery","status":"TERMINATED","sponsor":"Seattle Children's Hospital","startDate":"2011-07-15","conditions":"Hip Surgery, Post Operative Pain Control","enrollment":42},{"nctId":"NCT00726830","phase":"NA","title":"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03","conditions":"Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia","enrollment":1},{"nctId":"NCT03616639","phase":"PHASE4","title":"Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2018-06-04","conditions":"Pain, Terminal Illness, Renal Impairment","enrollment":8},{"nctId":"NCT00784472","phase":"PHASE3","title":"Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL","status":"COMPLETED","sponsor":"Katja venborg Pedersen","startDate":"2008-12","conditions":"Kidney Stones","enrollment":55},{"nctId":"NCT00831051","phase":"PHASE2","title":"Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2008-12","conditions":"Postoperative Pain","enrollment":197},{"nctId":"NCT00818493","phase":"PHASE2","title":"Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2009-02","conditions":"Postoperative Pain","enrollment":44},{"nctId":"NCT01016808","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2009-12","conditions":"Moderate to Severe Postoperative Pain","enrollment":522},{"nctId":"NCT00565760","phase":"PHASE3","title":"Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2007-11","conditions":"Acute Moderate to Severe Pain","enrollment":16},{"nctId":"NCT00560183","phase":"PHASE3","title":"Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2007-11","conditions":"Postoperative Pain","enrollment":256},{"nctId":"NCT01055015","phase":"PHASE3","title":"Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2010-02","conditions":"Postoperative Pain","enrollment":141},{"nctId":"NCT01280331","phase":"PHASE3","title":"Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients","status":"COMPLETED","sponsor":"QRxPharma Inc.","startDate":"2011-01","conditions":"Postoperative Pain","enrollment":375},{"nctId":"NCT00528177","phase":"PHASE4","title":"Morphine vs. Oxycodone for Postoperative Pain Management","status":"COMPLETED","sponsor":"Ullevaal University Hospital","startDate":"2007-09","conditions":"Hysterectomy, Myoma, Postoperative Pain","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Q8003","genericName":"Q8003","companyName":"QRxPharma Inc.","companyId":"qrxpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Q8003 is a selective inhibitor of the kappa opioid receptor. Used for Opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}